Charite Universitätsmedizin Berlin

Mainz 55124

0 studies enrolling now · 1 studies all time

What they study most

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

Studies at this site

• A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) — Stopped early